Rural Healthcare

State of play.

• The Trump administration has proposed a $50 billion Rural Health Transformation Program as the centerpiece of its FY 2027 HHS budget request, while simultaneously cutting funding for opioid programs and rural health offices — a structural tension that drew congressional scrutiny during Kennedy's April hearings .
• State legislatures are moving faster than federal regulators on telehealth access, with five states expanding scope-of-practice and fee structures in March 2026 alone — developments that directly affect rural provider networks operating across state lines .
• CMS has launched a 10-year ACO model aimed at increasing provider participation, a structural shift with direct implications for rural health systems evaluating value-based care entry points .
• The rural care crisis is being reframed as an economic viability problem, not merely a public health access gap — a framing with consequences for how rural hospital transactions, closures, and restructurings are analyzed .
• For counsel advising rural health systems, telehealth platforms, or ACO participants, the practical baseline is a bifurcated federal picture: a large proposed rural investment program whose funding mix is contested, and a CMS value-based care push that may be the more durable near-term lever.

Where things stand.

• The $50 billion Rural Health Transformation Program is a proposed budget item, not enacted law. Kennedy's FY 2027 request faces opposition from lawmakers concerned that proposed cuts to opioid treatment and rural health offices undercut the headline rural investment figure .
• CDC leadership instability creates regulatory uncertainty. With the CDC directorship having been filled for only 29 days since Trump took office, Dr. Erica Schwartz's nomination — pending Senate HELP Committee confirmation — represents the fourth director in over a year; regulatory priorities on rural public health remain unsettled .
• Telehealth's state-law patchwork is thickening. New Mexico has banned facility fees for telehealth; Virginia has established a Sickle Cell Network with specialist telehealth; West Virginia has authorized genetic counselor telehealth; South Carolina has authorized veterinary telehealth; Florida has designated naturopathic doctors as eligible telehealth providers — each statute carrying distinct licensure and compliance obligations .
• Federal telehealth extensions remain temporary. DEA telehealth prescribing extensions run through 2026; Medicare coverage determinations extend to 2027 — creating a compliance horizon that multi-state rural providers must track .
• CMS's 10-year ACO model is designed to lower the participation barrier for providers — including rural and safety-net systems — who have historically found shorter-cycle value-based models too risky to enter .
• Rural hospital economics are under structural pressure independent of federal program cycles. The economic-viability framing signals that closure risk, transaction activity, and restructuring are driven by market fundamentals, not just reimbursement policy .

Latest developments.

• Kennedy testified before four congressional committees on the FY 2027 HHS budget, pitching the $50 billion Rural Health Transformation Program while facing scrutiny over simultaneous cuts to opioid and rural health office funding .
• Trump nominated Dr. Erica Schwartz as CDC director; she holds both an MD and a JD and previously served as deputy surgeon general .
• Five states advanced telehealth legislation in March 2026, expanding scope of practice to genetic counselors, naturopathic doctors, and veterinary providers, and banning facility fees in New Mexico .
• CMS launched a 10-year ACO model intended to increase participation among providers currently outside value-based arrangements .
• Analysis reframes the rural care crisis as an economic issue, with implications for how counsel structures rural hospital transactions and evaluates closure risk .

Active questions and open splits.

• Whether the Rural Health Transformation Program survives budget negotiations intact. The proposed $50 billion figure is offset by cuts to opioid programs and rural health offices — a trade-off that may not survive appropriations; counsel advising rural systems should not treat the program as a funding certainty .
• How state telehealth expansions interact with federal DEA and Medicare frameworks. State laws authorizing new provider categories and banning facility fees may conflict with or outpace federal coverage and prescribing rules; multi-state compliance frameworks need to account for both layers .
• Whether the 10-year ACO model's participation incentives are sufficient for rural systems. The structural question is whether longer contract terms and adjusted risk parameters actually move rural and safety-net providers into value-based arrangements, or whether workforce and capital constraints remain the binding constraint .
• How the economic-viability framing reshapes rural hospital M&A and closure analysis. If rural hospital distress is primarily economic rather than policy-driven, the standard regulatory-approval and certificate-of-need analysis may underweight financial-sustainability factors in transaction review .
• CDC leadership continuity and its effect on rural public health regulatory output. With Schwartz's confirmation pending and the directorship having been largely vacant, the pace and direction of CDC guidance relevant to rural health programs — including opioid response — is uncertain .

What to watch.

• Senate HELP Committee action on the Schwartz CDC nomination — confirmation or delay will signal how quickly CDC regulatory priorities stabilize.
• Congressional appropriations markup of the FY 2027 HHS budget, specifically whether the Rural Health Transformation Program survives and at what funding level relative to the proposed opioid and rural office cuts.
• DEA telehealth prescribing rule developments before the 2026 extension expires — any tightening will directly affect rural providers dependent on remote prescribing.
• Additional state telehealth legislation in the second half of 2026, particularly facility-fee bans and scope-of-practice expansions that affect rural multi-state operators.
• CMS implementation guidance on the 10-year ACO model, including rural-specific participation terms and risk-adjustment parameters.